
Opinion|Videos|May 29, 2024
NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC
Author(s)Neal Shore, MD
Neal Shore, MD, FACS, describes the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in muscle-invasive bladder cancer (MIBC), and discusses the key efficacy results of pathologic complete response and major pathologic response rates.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- Describe the patient population and treatment regimen evaluated in the NURE-COMBO phase 2 trial of neoadjuvant nivolumab plus nab-paclitaxel followed by adjuvant nivolumab in MIBC. What were the key efficacy results in terms of pathologic complete response and major pathologic response rates?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
2
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
3
Physician Peer Influence Drives Uptake of Opportunistic Salpingectomy for Ovarian Cancer Prevention
4
Efgartigimod Outperforms Standard IVIG in Averting Myasthenic Crisis
5